MedTrace Logo

Mifepristone Treatment of Alcohol Use Disorder

NCT02179749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2022-10-06

Study results available
· View outcomes & findings →

Summary

This is an 8-week, randomized, double-blind, placebo-controlled, 2 arm, parallel groups, study of 1-week of treatment with mifepristone (0, 1200 mg/d) given in conjunction with 8 weeks of manual-guided counseling, and a follow-up visit at Week 12.

Conditions

  • Alcohol Dependence
  • Alcohol Use Disorders
  • Alcohol Abuse
  • Alcoholism

Interventions

DRUG

Mifepristone 1200 mg daily

Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.

BEHAVIORAL

Standardized behavioral therapy

Standardized behavioral therapy 1 time per week for 8 week duration.

DRUG

Placebo

Placebo tablets, Four tablets daily/am for 1-week duration.

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara J. Mason, Ph.D · The Scripps Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-11-30
Completion
2019-11-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02179749 on ClinicalTrials.gov